Heparin
(Synonyms: 肝素) 目录号 : GC10829肝素是一种高度硫酸化的糖胺聚糖,被广泛用作注射用抗凝剂,在任何已知生物分子中具有最高的负电荷密度。
Cas No.:9005-49-6
Sample solution is provided at 25 µL, 10mM.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Heparin, a highly sulfated glycosaminoglycan, has been widely used as an injectable anticoagulant. Heparin is present only in a few tissues and species of the animal kingdom and in the form of granules inside organelles in the cytoplasm of special cells. Heparin might be involved in defense mechanisms against bacteria and other foreign materials [1].
In vitro: Heparin (25-500 Nμ/ml) dose-dependently inhibited cellular aggregation and degranulation induced either by FMLP or by zymosan-activated serum. Heparin at the concentration of25 μg/ml specifically inhibited FMLP-dependent superoxide anion generation and chemiluminescence. Heparin inhibited all the aspects of the functional and metabolic granulocyte activation [2].
In vivo: In the cells from heparin-treated rats or in the heparin-treated cells, specific binding of [125I]iodo-angiotensin II was decreased due to a decrease in both the number and the affinity of angiotensin II receptors. Heparin also decreased the maximum angiotensin Il-induced productionof aldosterone in the cells from heparin-treated rats and in the heparin-treated cells. Heparin interacted with adrenal angiotensin II receptors to inhibit the angiotensin Il-induced aldosterone production [3].
References:
[1]. Nader H B, Chavante S F, Dos-Santos E A, et al. Heparan sulfates and heparins: similar compounds performing the same functions in vertebrates and invertebrates[J]. Brazilian Journal of Medical and Biological Research, 1999, 32(5): 529-538.
[2]. Pasini F L, Pasqui A L, Ceccatelli L, et al. Heparin inhibition of polymorphonuclear leukocyte activation in vitro. A possible pharmacological approach to granulocyte-mediated vascular damage[J]. Thrombosis research, 1984, 35(5): 527-537.
[3]. Azukizawa S, Iwasaki I, Kigoshi T, et al. Effects of heparin treatments in vivo and in vitro on adrenal angiotensin II receptors and angiotensin II-induced aldosterone production in rats[J]. Actaendocrinologica, 1988, 119(3): 367-372.
Cas No. | 9005-49-6 | SDF | |
别名 | 肝素 | ||
Canonical SMILES | CC(NC1C(O)C(OC2C(OS(=O)(O)=O)C(O)C(OC3C(NS(=O)(O)=O)C(OS(=O)(O)=O)C(OC4C(OS(=O)(O)=O)C(O)C(O)C(C(O)=O)O4)C(CO)O3)C(C(O)=O)O2)C(COS(=O)(O)=O)OC1O)=O | ||
分子式 | C26H42N2O37S5 | 分子量 | 1134.93 |
溶解度 | ≥ 12.75mg/ml in Water | 储存条件 | Store at -20°C, sealed storage, protect from light |
General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 |
制备储备液 | |||
1 mg | 5 mg | 10 mg | |
1 mM | 0.8811 mL | 4.4056 mL | 8.8111 mL |
5 mM | 0.1762 mL | 0.8811 mL | 1.7622 mL |
10 mM | 0.0881 mL | 0.4406 mL | 0.8811 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。